Tirzepatide carries a boxed warning regarding the risk of thyroid C-cell tumors based on rodent studies. Several patient populations should not use tirzepatide.
Absolute contraindications: personal or family history of medullary thyroid carcinoma (MTC); Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); pregnancy and breastfeeding (Pregnancy Category - withdraw 2 months before planning pregnancy); known hypersensitivity to tirzepatide. Relative contraindications: severe gastroparesis; history of pancreatitis; severe gastrointestinal disease; history of severe diabetic retinopathy.
This page references peer-reviewed publications listed on PubMed and FDA prescribing information labels. Methodology for source selection is documented on the Methodology page.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000